



Gelclair

Literary Review



December 2013 to March 2014

Title	Publication	Date	Overview
People with throat cancers are slowest to present to GP, audit finds	BMJ, Vol 348, No. 7945, page 2.	15 February	Data from a recent audit has shown that patients with oesophageal and oropharyngeal cancer took on average 22 and 30 days respectively to see their GP after first noticing symptoms. Bladder and kidney cancer patients took only 2 - 3 days, with the median for all cancers being 10 days.
Vote to ban smoking in cars with children is a victory for child health	BMJ, Vol 348, No. 7945, page 5.	15 February	Article discussing the recent decision by MPs to allow government to ban smoking in cars with children and what this might mean for children's health and the NHS.
Are e-cigarettes a safer alternative to smoking	Nursing Times, Vol. 110, No. 7, pages 20-21.	12 February	Article discussing the use of e-cigarettes as a replacement to cigarettes in terms of its delivery of nicotine, research and how it compares to traditional stop-smoking options.
Advanced radiation therapy may have higher survival rates for head and neck cancers	Nursing Standard, Vol. 28, No. 24, page 17.	12 February	Summary of a recent study which looked at intensity-modulated radiation therapy (IMRT) for head and neck cancers. This therapy, designed to minimise side effects such as dry mouth, swallowing difficulties and bone destruction, has also been analysed for its efficacy. The results show 84.1% survival with IMRT vs. 66% survival with traditional radiation (median follow up: 40 months, n=3,172).
Global cancer patterns: Causes and preventions	The Lancet, Vol. 383, No. 9916, pages 549-557.	8 February	Article looking at the globalisation of cancer and its trends. It also discusses the major risk factors and primary prevention.
Oesophageal cancer	Nursing Standard, Vol. 28, No. 25, page 19.	19 February	Facts and figures article on oesophageal cancer which includes information on survival rates, signs and symptoms and associated risk factors.

Cont. overleaf

Visit www.gelclair.co.uk for free sample packs and more information on Gelclair





Literary Review, cont.



December 2013 to March 2014

Title	Publication	Date	Overview
Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: a randomised controlled trial	British Journal of Cancer, Vol. 110 No. 3, pages 593-601.	4 February	Study investigating the effect of nurse counselling and after intervention (NUCAI) on health-related quality of life and depressive symptoms of head and neck cancer patients, 12 and 24 months after cancer treatment.
¹⁸ F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma	British Journal of Cancer, Vol. 109 No. 12, pages 2973-2979.	10 December	Study results which looked at whole-body fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸ F-FDG PET/CT) plus regular clinical follow-up after curative treatment for detection of recurrence.
Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance	British Journal of Cancer, Vol. 110 No. 2, pages 479-488.	4 February	Analysis of results from tumour-derived slice cultures, which were kept in vitro for at least 6 days and treated with cisplatin, docetaxel and cetuximab.
Head and Neck Cancer: Historical Evolution of Treatment and Patient Self-Care Requirements	Clinical Journal of Oncology Nursing, Vol.17, No. 6, pages 659-663.	December	Review article which explores the historical progression of treatment and patient care/self-care requirements, including how to cope with physical changes in appearance.
Analysis of time taken to discuss new patients with head and neck cancer in multidisciplinary team meetings	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 1, pages 128-133.	January	Evaluation paper which looked at the discussion time, per head and neck cancer patient, in multidisciplinary team meetings. The average time was 2 minutes, although advanced stage patients were longer and early stage tumours shorter discussions.

Cont. overleaf

Visit www.gelclair.co.uk for free sample packs and more information on Gelclair





Literary Review, cont.



December 2013 to March 2014

Title	Publication	Date	Overview
Experience of head and neck theatre staff and attitudes to human factors using an aviation-based analysis and classification system - a pilot survey	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 1, pages 38-42.	January	Questionnaire results from 140 head and neck staff working in operating theatres, which looked at human factors related to medical errors. Most positive responses were found in the consultant group followed by trainee doctors and support staff. A significant difference was found in the subcategories of Unsafe Supervision ($p = 0.002$) and Preconditions to Unsafe Acts ($p = 0.001$).
Health-related quality of life of patients treated with primary chemoradiotherapy for oral cavity squamous cell carcinoma: a comparison with surgery	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 2, pages 111-117.	February	Article which looks at the health-related quality of life (QoL) of patients with SCC of the oral cavity who were treated with chemoradiotherapy, vs. those treated with conventional surgery with or without adjuvant treatment. The overall outcome for both treatments in all groups were reasonably high, suggesting that both treatments provided acceptable health-related QoL.
Is nicotine still the bad guy? Summary of the effects of smoking on patients with head and neck cancer in the postoperative period and the uses of nicotine replacement therapy in these patients	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 2, pages 102-105.	February	Article summarising the effects that smoking and abstaining from smoking can have on inflammation and wound healing. It also describes the possible benefits that nicotine used in isolation may have on healing.
Intraoral adenoid cystic carcinoma: is the presence of perineural invasion associated with the size of the primary tumour, local extension, surgical margins, distant metastases, and outcome?	British Journal of Oral and Maxillofacial Surgery, Vol. 52, No. 3, pages 214-218.	March	Article reviewing 26 cases of adenoid cystic carcinoma of the intraoral salivary, which looked at the most common sites, size of tumour and perineural invasion.

Visit www.gelclair.co.uk for free sample packs and more information on Gelclair

Take away the pain of oral mucositis...



with

 **gelclair**[®]



- Gelclair is a **highly effective barrier-forming gel**¹⁻³ specially formulated to aid in the management of lesions of the oral mucosa.
 - Has been shown to reduce pain in 86% of patients.⁴
- Gelclair is available in easy to use sachets.
- **Starter packs** are available to order free of charge from our website.



In an online survey, 92% of patients are satisfied with Gelclair and would recommend to other oral mucositis patients.⁵

For more information on Gelclair or to request a free starter pack, as well as access to helpful resources including patient case study videos, please visit www.gelclair.co.uk, call our Customer Services team on **01249 466 966**, or email us at medinfo@alliancepharma.co.uk

References: 1. Innocenti M et al. *J Pain Symptom Manage* 2002; 24(5): 456-457. 2. McLean M. Poster presented at the British Association of Head and Neck Oncology Nurses National Study Day on Sharing Good Practice in Head and Neck Cancer Nursing, 12 June 2009. 3. Gibson et al. Presented at SIOP 2010. 4. Kantardžić N et al., *The Internet Journal of Oncology* 2009; 6(2). 5. Data on file: Patient online feedback. Correct as of January 2014.

 **ALLIANCE**
Breathing life into medicines

Medical device incidents should be reported. Reporting information can be found at www.mhra.gov.uk
Adverse events should also be reported to Pharmacovigilance at Alliance Pharmaceuticals
(tel: 01249 466 966, email: pharmacovigilance@alliancepharma.co.uk)


It's got oral mucositis covered